Kevin Reilly Sells 2,932 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Kevin Reilly sold 2,932 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $25.13, for a total value of $73,681.16. Following the completion of the sale, the director directly owned 5,368 shares of the company’s stock, valued at approximately $134,897.84. This trade represents a 35.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 3.1%

KMTS stock opened at $22.85 on Friday. The firm has a market capitalization of $1.34 billion, a PE ratio of -9.44 and a beta of 0.62. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a twelve month low of $17.34 and a twelve month high of $30.00. The stock’s 50 day moving average is $25.34 and its 200-day moving average is $22.71.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Analyst Ratings Changes

KMTS has been the subject of several analyst reports. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Oppenheimer started coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. Finally, BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, September 2nd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $28.14.

Key Headlines Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
• Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
• Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
• Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Institutional Investors Weigh In On Kestra Medical Technologies

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its stake in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the period. Rhumbline Advisers grew its position in Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock valued at $307,000 after buying an additional 874 shares during the period. Police & Firemen s Retirement System of New Jersey increased its holdings in Kestra Medical Technologies by 34.6% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after buying an additional 1,392 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.